aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Achelios Therapeutics, founded in Chapel Hill, United States, is dedicated to developing advanced NSAID products with superior tissue penetration using their proprietary ACHETOGEL™ delivery technology. Their core mission is to provide effective topical treatments for pain and inflammation, targeting conditions such as temporomandibular joint disorder (TMJD), menstrual migraines, and chronic inflammatory joint pain. Their lead product, TOPOFEN™, utilizes the NSAID ketoprofen and has demonstrated promising results in pre-clinical and early-stage clinical studies.
Achelios Therapeutics has garnered attention for its innovative approach to pain management, attracting notable investors and industry experts. The company's achievements include securing patents for their unique delivery technology and advancing TOPOFEN™ through critical stages of development. Their impact lies in offering non-invasive, effective alternatives to traditional pain relief methods, potentially improving the quality of life for individuals suffering from chronic pain conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
NSAID Products
Technology
Biotech
Tags
Healthtech
Model Types
Biotech
Revenue Type(s)
Licensing
Customer Type(s)
Small Business
Geographic Exposure
United States
When was Achelios Therapeutics founded?
Achelios Therapeutics was founded in 2012.
Where is Achelios Therapeutics’s headquarters located?
Achelios Therapeutics’s headquarters is located in Chapel Hill, NC, US.
When was Achelios Therapeutics’s last funding round?
Achelios Therapeutics’s most recent funding round was for $350k (USD) in April 2016.
How many employees does Achelios Therapeutics have?
Achelios Therapeutics has 5 employees as of Feb 5, 2024.
How much has Achelios Therapeutics raised to-date?
As of July 05, 2023, Achelios Therapeutics has raised a total of $3.5M (USD) since Apr 19, 2016.
Add Comparison
Total Raised to Date
$3.5M
USD
Last Update Apr 19, 2016
Last Deal Details
$350k
USD
Apr 19, 2016
Debt Financing
Total Employees Over Time
5
As of Feb 2024
Achelios Therapeutics Address
6340 Quadrangle Drive
Suite 120
Chapel Hill,
North Carolina
27517
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts